Immuneering Corporation - Class A Common Stock — Quarterly Balance Sheet (NASDAQ:IMRX) | MetaTrader

Open full chart

News

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'

Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS)

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

The 'Unprecedented' Cancer Test Results That Sent Revolution Medicines Flying

3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts - TipRanks.com

Piper Sandler cuts Immuneering stock price target on launch timing

Oppenheimer reiterates Immuneering stock rating on pipeline progress

Immuneering’s (IMRX) chief business officer buys $24,990 in stock

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.55%